Mental Health Issues Triple Among UK Students

Updated Feb 20, 2025 | 08:55 AM IST

SummaryAs per the latest data, the number of mental health cases tripled among students in the UK. The worse affected are LGBTQ students and women.
Mental Health Issues Triple Among UK Students

Credits: Canva

As per the latest data released by Transforming Access to Student Outcomes in Higher Education (TASO) and the Policy Institute at King's College London, the number of UK students reporting mental health difficulties tripled. The estimate reveals that around 300,000 students could now be experiencing mental health struggles. Of the total, 18% of students reported some kind of mental health issue in 2024.

As per the reports, this estimate is triple what was reported in 2017, where it was at 6%. Experts also say that Covid-19 pandemic is "often considered to have contributed to this, it does not explain the ongoing rise in mental health difficulties." Another reason could also be the "changing definition and increasing openness about mental health" which has led to a rise in numbers. The report notes, "This trend pre-dates the Covid-19 pandemic and the cost-of-living crisis. Although these factors play a part in students' deteriorating mental health, they cannot therefore be the only explanation."

How Did The Report Conclude?

The report drew data collected over the latest Student Academic Experience Survey of 93,212 students. From the survey, it was found that there exist significant disparities between demographic groups, with women being twice as likely to report mental health difficulties, about 22% as compared to men, at 11%.

What Did The Results Reveal?

The results revealed that students who identified as LGBTQ experienced the highest rates of mental health challenges. This has actually lessened the hope that conditions for LGBTQ students are improving, which may not have been a positive case.

Of them, 42% are bisexual and lesbian students, whereas last year it was 35% and 32% respectively. The report also noted that mental health difficulties among lesbian women and gay men rose three times the rate of straight people, and among bisexual and asexual people, it was twice as high. For trans students, the number jumped from 25% in 2023 to 40% in 2024.

Is The LGBTQ+ Prone To Mental Health Crisis?

As per the Child Mind Institute, being LGBTQ+ does not cause mental health problems, but because these kids often face factors like rejection, discrimination and violence, they are at a higher risk of challenges including depression, anxiety, and even attempting suicide.

A UTAH Health study quotes Anna Docherty, PhD, LP, assistant professor of psychiatry at Huntsman Mental Health Institute that, "likely with any identity, feeling different - or worse, unaccepted as you are is a significant risk factor of mental health struggle." The data reveals that LGBTQ+ teens are six times more likely to experience symptoms of depression than non-LGBTQ+ identifying teens. They are also more than twice as likely to feel suicidal and more than four times as likely to attempt suicide. In the US alone, 48% of transgender adults report that they have considered suicide in the last year, compared to 4% of the overall population.

What Do These Findings Mean?

TASO's academic lead and professor of public policy at King's College London, Michael Sanders said, "LGBTQ students and women bear the brunt of the rise in declining mental health and urgent action is needed to understand and address these trends."

End of Article

Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer

Updated Nov 17, 2026 | 08:46 AM IST

SummaryThe European Commission granted marketing authorisation to Revolution Medicines to produce and sell RASONQUE (daraxonrasib) to treat aggressive metastatic pancreatic adenocarcinoma.
Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer

Credit: AI-generated image

The European Commission has approved RASONQUE (daraxonrasib), a targeted cancer medicine developed by Revolution Medicines, for patients with metastatic pancreatic adenocarcinoma.

The approval marks a milestone in advanced pancreatic cancer treatment, offering an alternative to chemotherapy, especially for patients whose cancer has progressed despite earlier treatment.

RASONQUE is an oral medication which is taken once daily. It is the first broad RAS-targeted medicine approved in Europe for metastatic pancreatic cancer and can be used in patients with or without an identified RAS tumour mutation.

The approval applies to all European Union member states and the European Economic Area countries Iceland, Norway and Liechtenstein. It does not extend to the UK or Switzerland, which have separate regulatory approval processes.

More About RASONQUE

Pancreatic adenocarcinoma, the most common form of pancreatic cancer, is driven by alterations in the RAS genes. These genes produce proteins that are involved in regulating cell growth. When mutations keep RAS proteins active, they can drive uncontrolled cancer cell growth.

Around 147,000 people are diagnosed with pancreatic cancer in Europe each year. The five-year survival rate is also below 10%. As early-stage pancreatic cancer shows few or no symptoms, approximately 80% of patients are diagnosed after the disease has spread.

Daraxonrasib works by blocking RAS proteins, which can become overactive in cancer cells and send signals that tell them to grow and multiply. It binds to a protein called cyclophilin A to form a complex that attaches to these active RAS proteins, preventing them from sending growth signals. This helps stop the cancer cells from growing and spreading.

Unlike treatments that target a single RAS mutation, daraxonrasib inhibits multiple RAS variants.

Also read: Bowel, Pancreatic & Liver: NHS Trial Offers New Blood Test To 20,000 Patients That Could Detect 13 Cancers

What Did The Clinical Trial Find?

The European Commission's decision was based on results from the Phase 3 RASolute 302 trial, which compared daraxonrasib with standard chemotherapy in 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma. Approximately 92% of participants had confirmed RAS G12 mutations.

According to the European Medicines Agency (EMA), patients receiving daraxonrasib had a median overall survival of 12.4 months, compared to 6.7 months among those receiving chemotherapy.

Median progression-free survival, which measures how long patients live without their disease worsening, was 7.2 months with daraxonrasib versus 3.6 months with chemotherapy.

The US Food and Drug Administration (FDA), which approved the drug in August 2026, also reported improvements in overall survival and progression-free survival in both patients with RAS G12 mutations and the overall trial population.

Also read: New Pancreatic Cancer Vaccine Triggers Immune Response In 99% Of Patients

What Are The Side Effects?

The most commonly reported side effects of daraxonrasib include diarrhoea, skin rash, stomatitis (inflammation of the mouth lining), nausea and vomiting.

The drug also carries warnings for serious complications like severe skin and soft tissue reactions, gastrointestinal perforation and interstitial lung disease or pneumonitis.

Although the European Commission has granted approval, patient access will depend on individual countries completing their pricing, health technology assessment and reimbursement processes.

Revolution Medicines said it is working with healthcare systems and relevant stakeholders across Europe to enable access to the treatment.

The approval follows an expedited assessment under the EMA's Cancer Medicines Pathfinder project, which aims to accelerate the evaluation of promising medicines addressing significant unmet medical needs.

End of Article

Popular Blood Pressure Medicine Propranolol Recalled In The US Over Possible Metal Contamination

Updated Nov 17, 2026 | 07:24 AM IST

SummaryPropranolol Hydrochloride Extended-Release Capsules, USP 60 mg, manufactured by Adare Pharma Solutions, were recalled voluntarily in the US due to concerns that it may contain metal particles.
Popular Blood Pressure Medicine Propranolol Recalled In The US Over Possible Metal Contamination

Credit: AI-generated image

Breckenridge Pharmaceutical, Inc. has announced a voluntary nationwide recall of a batch of Propranolol Hydrochloride Extended-Release Capsules, USP 60 mg in the US over concerns that the medication may contain metal particles.

The recall, announced on November 16, 2026, covers one lot of the blood pressure medication manufactured by Adare Pharma Solutions. The company initiated the recall after identifying a possible contamination linked to an intermediate material used in the affected batch.

According to the company's recall notice, the contaminated material was suspected to be the source of metal contamination identified in a separate lot that was not released into the market.

Risk Of Injuries To The Digestive Tract

The company has warned that taking capsules from the affected lot could cause physical injuries to soft tissues in the body.

According to the recall notice, use of the affected product could cause "lacerations of soft tissues in the oral cavity, esophagus, stomach, or intestine."

However, Breckenridge Pharmaceutical stated that it was not aware of any adverse events related to the recall at the time of the announcement.

The affected products were distributed to wholesalers and pharmacies across the US between October 26 and November 4, 2026.

Also read: From 4 To 100 Kratom Capsules A Day: Woman Shares Warning Signs Of Addiction

Which Propranolol Batch Has Been Recalled?

The recall is limited to a specific batch of 60 mg Propranolol Hydrochloride Extended-Release Capsules. The details are:

  • Product: Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg
  • Package size: 100-count bottle
  • NDC number: 51991-817-01
  • Affected lot number: PK25110035
  • Expiry date: May 2029

Those who have been prescribed the pill between the dates mentioned above are advised to check the product packaging and lot number to determine whether their medication is part of the recall.

Also read: Popular Anti-Anxiety Capsules Recalled Over Salmonella Fears: What Should Patients Know

What Should Patients Do?

Breckenridge Pharmaceutical has advised consumers to immediately stop taking the medication from the affected lot and contact their physician or healthcare provider for medical advice for obtaining a replacement.

"Consumers should return any unused portion of the affected product to the pharmacy where it was obtained," the company's announcement said.

Patients should also return any unused capsules from the recalled batch to the pharmacy where they purchased the medication. Anyone who has experienced health problems that could be due to the recalled medicine should contact their healthcare provider.

Pharmacies, wholesalers and other retailers have been instructed to check their inventories, quarantine the affected products and stop distributing or dispensing them.

Consumers seeking additional information about the recall can contact Qualanex, the company's designated recall service provider, at 1-855-736-0807 or email recall@qualanex.com. The recall is being conducted with the knowledge of the US Food and Drug Administration (FDA).

Also read: US FDA Recalls Thousands Of Blood Pressure Drugs Over Excess Drug Levels, Failed Quality Tests

What Is Propranolol Used For?

Propranolol belongs to a class of medicines called beta-blockers. It works by reducing the effects of certain stress hormones on the heart, thereby slowing the heart rate and reducing blood pressure.

The medication is commonly prescribed to manage high blood pressure and other cardiovascular conditions. It is also used for certain heart rhythm disorders, angina and migraine prevention.

The extended-release formulation is designed to release the medicine gradually over time, allowing effects that last long.

Propranolol's recall is the latest in a series of recent blood pressure medication recalls, including a recent one involving Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide tablets. They were recalled as they did not dissolve properly. A while go, Chlorthalidone tablets were also recalled for the same reason.

End of Article

Bean-Based Chewing Gum Cuts HPV Levels By Up To 93%: Could It Help Prevent Cancer?

Updated Nov 17, 2026 | 12:00 AM IST

SummaryResearchers found that extracts of the bean-based gum reduced HPV levels by up to 93% in oral samples from patients with head and neck cancer.
Bean-Based Chewing Gum Cuts HPV Levels By Up To 93%: Could It Help Prevent Cancer?

Credit: iStock

Could chewing gum one day help fight cancer? Researchers at the University of Pennsylvania in the US have developed an experimental gum made from lablab beans, also known as Indian beans, that targets human papillomavirus (HPV) and harmful oral bacteria associated with head and neck cancer.

In laboratory tests using oral samples from cancer patients, extracts of the gum reduced HPV levels by up to 93%. An enhanced version also reduced two harmful bacterial species to nearly undetectable levels without affecting the beneficial bacteria tested.

How Does The Bean-Based Chewing Gum Work?

The experimental gum builds on the team's earlier research into lablab beans. It contains FRIL, a naturally occurring plant protein with antiviral properties.

Researchers tested gum extracts against microorganisms in oral samples collected from patients with head and neck cancer.

The results published in Scientific Reports journal showed:

  • HPV levels decreased by 93% in saliva samples.
  • HPV levels decreased by 80% in oral rinse samples.

The researchers also developed an enhanced version containing protegrin, an antimicrobial peptide. Peptides are short chains of amino acids, the building blocks of proteins.

A single dose of the enhanced gum extract reduced two targeted bacterial species, Porphyromonas gingivalis (Pg) and Fusobacterium nucleatum (Fn), to nearly undetectable levels.

Also read: HPV Vaccines Can Prevent Head And Neck Cancers In Men, Says Study

Harmful Bacteria Reduced Without Affecting Beneficial Microbes

The experimental formulation selectively targeted harmful bacteria while leaving the beneficial bacterial populations examined in the study largely unaffected.

The oral microbiome, which consists of microorganisms living inside the mouth, plays an important role in maintaining oral health.

Cancer treatments such as radiation therapy can disrupt this microbial balance, reducing beneficial bacteria and encouraging the growth of potentially harmful microorganisms, including Candida albicans, a type of yeast.

The researchers suggest that selectively targeting harmful microbes while preserving beneficial ones could be particularly useful for patients undergoing cancer treatment.

Read More: Russia's mRNA Cancer Vaccine: First Patient With Melanoma Completes Treatment, Shows No New Tumours

Could The Chewing Gum Help Prevent Cancer?

The researchers believe the findings warrant further investigation through human clinical trials. They envision the technology potentially being used alongside existing cancer treatments or as a preventive approach to limit infections.

"Lip and oral cavity cancer was the seventh leading cancer type in cancer incidence and mortality rate worldwide in adolescents, young adults, and middle-aged adults in 2022," Daniell said.

He said the findings support advancing these therapies into clinical trials as additional treatments or as prophylaxis to prevent infection and transmission.

Prophylaxis refers to measures taken to prevent a disease or infection before it occurs.

The plant-based technology could also offer a potentially affordable way to deliver protective proteins directly into the mouth.

However, the findings should be interpreted cautiously. The researchers tested gum extracts on patient samples under laboratory conditions. They have not established whether chewing the gum produces the same results in people or whether reducing these microorganisms can prevent cancer or improve treatment outcomes.

Human clinical trials will be needed to establish its safety and effectiveness. For now, the bean-based gum remains experimental and is not a proven cancer-prevention or treatment option.

End of Article